#JPM23: BeiGene CEO John Oyler on the com­pa­ny's big am­bi­tions

BeiGene CEO John Oyler and End­points News Ex­ec­u­tive Ed­i­tor Drew Arm­strong spoke one-on-one about where the drug­mak­er is head­ed in its quest to be­come a di­ver­si­fied multi­na­tion­al, and what it will take to get there. This tran­script has been edit­ed for brevi­ty and clar­i­ty.

Drew Arm­strong:

I am joined to­day by BeiGene CEO John Oyler. By way of in­tro­duc­tion, John and I met about a lit­tle over three years ago for the first time in Bei­jing, when I was do­ing some re­port­ing. I got to trav­el around the coun­try and I had this huge note­book full of re­port­ing on in­ter­est­ing things that his com­pa­ny was do­ing and some of the oth­er com­pa­nies were do­ing over there. And I came back to the states ready to write a great mag­a­zine sto­ry about BeiGene and about in­no­va­tion that was hap­pen­ing glob­al­ly. And then I think we all know what hap­pened about a week and a half af­ter I re­turned, in Jan­u­ary of 2020. And un­for­tu­nate­ly that work nev­er saw the light of day.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER